11/15
08:04 am
tcrx
TScan Therapeutics, Inc. (NASDAQ: TCRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $15.00 price target on the stock.
Medium
Report
TScan Therapeutics, Inc. (NASDAQ: TCRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $15.00 price target on the stock.
11/14
05:32 am
tcrx
TScan Therapeutics Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag [Yahoo! Finance]
Medium
Report
TScan Therapeutics Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag [Yahoo! Finance]
11/12
12:36 pm
tcrx
TScan Therapeutics, Inc. (NASDAQ: TCRX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $11.00 price target on the stock.
Low
Report
TScan Therapeutics, Inc. (NASDAQ: TCRX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $11.00 price target on the stock.
11/12
09:49 am
tcrx
TScan Therapeutics GAAP EPS of -$0.25, revenue of $1.04M Nov. 12, 2024 9:48 AM ET By: Urvi Shah , SA News Editor [Seeking Alpha]
Medium
Report
TScan Therapeutics GAAP EPS of -$0.25, revenue of $1.04M Nov. 12, 2024 9:48 AM ET By: Urvi Shah , SA News Editor [Seeking Alpha]
11/12
07:00 am
tcrx
TScan Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Medium
Report
TScan Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
11/7
06:39 am
tcrx
TScan Therapeutics (TCRX) Soars 7.6%: Is Further Upside Left in the Stock? [Yahoo! Finance]
Medium
Report
TScan Therapeutics (TCRX) Soars 7.6%: Is Further Upside Left in the Stock? [Yahoo! Finance]
11/6
08:07 am
tcrx
TScan Therapeutics, Inc. (NASDAQ: TCRX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $11.00 price target on the stock.
Medium
Report
TScan Therapeutics, Inc. (NASDAQ: TCRX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $11.00 price target on the stock.
11/5
06:24 pm
tcrx
TScan Therapeutics, Inc. (NASDAQ: TCRX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $10.00 price target on the stock.
Low
Report
TScan Therapeutics, Inc. (NASDAQ: TCRX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $10.00 price target on the stock.
11/5
09:15 am
tcrx
TScan Therapeutics Announces Upcoming Oral Presentation of Data from the ALLOHA™ Phase 1 Heme Trial at the 66th American Society of Hematology Annual Meeting and Exposition
Medium
Report
TScan Therapeutics Announces Upcoming Oral Presentation of Data from the ALLOHA™ Phase 1 Heme Trial at the 66th American Society of Hematology Annual Meeting and Exposition
10/4
09:05 am
tcrx
TScan Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 39th Annual Meeting
Medium
Report
TScan Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 39th Annual Meeting
8/29
07:00 am
tcrx
TScan Therapeutics to Participate in Upcoming Investor Conferences
Low
Report
TScan Therapeutics to Participate in Upcoming Investor Conferences
8/29
06:28 am
tcrx
Director of TScan Therapeutics Barbara Klencke Buys 18% More Shares [Yahoo! Finance]
Low
Report
Director of TScan Therapeutics Barbara Klencke Buys 18% More Shares [Yahoo! Finance]